Usefulness of bone resorption markers in hemodialysis patients

Bone

Volumn 45, Issue SUPPL. 1, 2009, Pages

  Hamano, Takayuki ^a   Tomida, Kodo ^a   Mikami, Satoshi ^a   Matsui, Isao ^a   Fujii, Naohiko ^b   Imai, Enyu ^a   Rakugi, Hiromi ^a   Isaka, Yoshitaka ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hyogo Prefectural Nishinomiya Hospital   (Japan)

Author keywords

1 84 PTH; CKD MBD; NTX; TRAP5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; BIOLOGICAL MARKER; COLLAGEN TYPE 1; PARATHYROID HORMONE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE DENSITY; CONTROLLED STUDY; FEMALE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; METACARPAL BONE; OSTEOCLAST; OSTEOLYSIS; PARATHYROIDECTOMY; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SEX DIFFERENCE;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BONE DENSITY; BONE RESORPTION; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ISOENZYMES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARATHYROIDECTOMY; PEPTIDES; REGRESSION ANALYSIS; RENAL DIALYSIS; SEX CHARACTERISTICS;

EID: 67349278081     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.03.663     Document Type: Article

References (27)

1. National Kidney Foundation:K/DOQI Clinical Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003;42 (suppl. 3):S1-S202;
2. Ureña P., and De Vernejoul M.C. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 55 6 (1999; Jun) 2141-2156
3. Ueda M., Inaba M., Okuno S., Maeno Y., Ishimura E., Yamakawa T., et al. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sci. 77 (2005) 1130-1139
4. Ureña P., Hruby M., Ferreira A., Ang K.S., and de Vernejoul M.C. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J. Am. Soc. Nephrol. 7 3 (1996; Mar) 506-512
5. Blayney M.J., Pisoni R.L., Bragg-Gresham J.L., Bommer J., Piera L., Saito A., et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitalization and death. Kidney Int. 74 5 (2008; Sep) 655-663
6. Regidor D.L., Kovesdy C.P., Mehrotra R., Rambod M., Jing J., McAllister C.J., et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J. Am. Soc. Nephrol. 19 11 (2008 Nov) 2193-2203
7. Maeno Y., Inaba M., Okuno S., Yamakawa T., Ishimura E., and Nishizawa Y. Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clin Chem. 51 12 (2005; Dec) 2312-2317
8. Asci G., Kircelli F., Sevinc E., Duman S., Ozkahya M., Toz H., et al. Bone markers for non-invasive diagnosis of adynamic bone disease in hemodialysis patients. J. Am. Soc. Nephrol. 19: 4A (2008)
9. Hamano T., Fujii N., Nagasawa Y., Isaka Y., Moriyama T., Okada N., et al. Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease. Bone 39 5 (2006; Nov) 1067-1072
10. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., and Väänänen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 15 (2000) 1337-1345
11. Väänänen H.K., Zhao H., Mulari M., and Halleen J.M. The cell biology of osteoclast function. J. Cell Sci. 113 (2000) 377-381
12. Yamada S., Inaba M., Kurajoh M., Shidara K., Imanishi Y., Ishimura E., et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin. Endocrinol. (Oxf) 69 2 (2008; Aug) 189-196
13. Chu P., Chao T.Y., Lin Y.F., Janckila A.J., and Yam L.T. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am. J. Kidney Dis. 41 5 (2003; May) 1052-1059
14. Ohashi T., Igarashi Y., Mochizuki Y., Miura T., Inaba N., Katayama K., et al. Nomura F Development of a novel fragments absorbed immunocapture enzyme assay system for tartrateresistant acid phosphatase 5b. Clin. Chim. Acta 376 (2007) 205-212
15. Payne R.B., Little A.J., Williams R.B., and Milner J.R. Interpretation of serum calcium in patients with abnormal serum proteins. Br. Med. J. 4 (1973) 643-646
16. Katagiri M., Ohtawa T., Fukunaga M., and Harada T. Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism. Surg. Today 25 7 (1995) 598-604
17. Rosholm A., Hyldstrup L., Backsgaard L., Grunkin M., and Thodberg H.H. Estimation of bone mineral density by digital X-ray radiogrammetry: theoretical background and clinical testing. Osteoporos Int. 12 11 (2001) 961-969
18. Hamano T., Oseto S., Fujii N., Ito T., Katayama M., Horio M., et al. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients. Bone 36 5 (2005 May) 909-916
19. Yajima A., Inaba M., Ogawa Y., Tominaga Y., Tanizawa T., Inou T., et al. Significance of time-course changes of serum bone markers after parathyroidectomy in patients with uraemic hyperparathyroidism. Nephrol. Dial. Transplant. 22 6 (2007; Jun) 1645-1657
20. Eriksen E.F., Melsen F., and Mosekilde L. Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Metab. Bone Dis. Relat. Res. 5 (1984) 235-242
21. Eriksen E.F., Gundersen H.J., Melsen F., and Mosekilde L. Reconstruction of the formative site in iliac trabecular bone in 20 normal individuals employing a kinetic model for matrix and mineral apposition. Metab. Bone Dis. Relat. Res. 5 (1984) 243-252
22. Franke S., Lehmann G., Abendroth K., Hein G., and Stein G. PICP as bone formation and NTx as bone resorption maker in patients with chronic renal failure. Eur. J. Med. Res. 21 3 (1998) 81-88
23. Nishizawa Y., Inaba M., Ishii M., Yamashita H., Miki T., Goto H., et al. Reference intervals of serum tartrate-resistant acid phosphatase type 5b activity measured with a novel assay in Japanese subjects. J. Bone Miner. Metab. 26 3 (2008) 265-270
24. Grandaliano G., Gesualdo L., Schena F.P., and Pertosa G. Clinical relevance of cytokine production in hemodialysis. Kidney Int. Suppl. 76 (2000 Aug) S104-S111
25. Kaji H., Sugimoto T., Kanatani M., Nasu M., and Chihara K. Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cyclic adenosine monophosphate pathway. Endocrinology 137 6 (1996; Jun) 2217-2224
26. Hernández E., Valera R., Alonzo E., Bajares-Lilue M., Carlini R., Capriles F., et al. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int. 63 6 (2003 Jun) 2269-2274
27. Shidara K., Inaba M., Okuno S., Yamada S., Kumeda Y., Imanishi Y., et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int. 82 4 (2008 Apr) 278-287